Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Kura Oncology is a clinical-stage biopharmaceutical company developing precision medicines for cancer, with lead asset ziftomenib (menin inhibitor) in Phase 2 trials for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) with KMT2A rearrangements or NPM1 mutations. The company's pipeline includes tipifarnib (farnesyltransferase inhibitor) for head and neck squamous cell carcinoma with HRAS mutations. Stock performance depends entirely on clinical trial readouts, regulatory milestones, and cash runway management as the company generates minimal revenue.
Pre-commercial biotech model: company burns cash developing drug candidates through clinical trials, with value creation tied to successful trial outcomes and eventual FDA approval. Ziftomenib targets genetically defined AML/ALL patient populations (estimated 2,000-3,000 US patients annually with KMT2A-r or NPM1-mutated relapsed/refractory disease). Monetization occurs through either: (1) commercial launch post-approval with specialty oncology sales force, (2) partnership/licensing deals with larger pharma companies, or (3) acquisition. Pricing power in rare oncology indications typically supports $150,000-$250,000 annual treatment costs. Operating leverage is negative until commercialization - fixed R&D costs dominate with minimal variable costs.
Ziftomenib Phase 2 clinical trial data readouts in NPM1-mutated and KMT2A-rearranged AML/ALL (complete response rates, overall survival, duration of response)
FDA regulatory interactions and potential breakthrough therapy designation or accelerated approval pathway discussions
Cash runway updates and equity financing announcements (dilution risk vs. funding security trade-off)
Partnership or licensing deal announcements with major pharma companies for development/commercialization rights
Competitive clinical data from rival menin inhibitors (Syndax Pharmaceuticals' revumenib, Janssen's JNJ-75276617)
Clinical trial failure risk: Phase 2/3 trials have 30-40% historical success rates in oncology; negative efficacy or safety data could render pipeline worthless
Regulatory approval uncertainty: FDA may require additional trials, reject applications, or impose restrictive labels limiting commercial opportunity
Reimbursement pressure: Payers increasingly scrutinizing high-cost oncology drugs, potentially limiting pricing power even post-approval
Patent cliff and intellectual property challenges: Composition of matter patents and regulatory exclusivity determine commercial runway and generic competition timing
Menin inhibitor competition: Syndax's revumenib is in similar development stage with potentially faster timeline; first-to-market advantage critical in rare disease oncology
Standard of care evolution: Venetoclax combinations and other targeted therapies improving outcomes in NPM1/KMT2A populations, raising efficacy bar for approval
Larger pharma entrants: Companies like Janssen, Novartis have greater resources for clinical development and commercial infrastructure if they prioritize menin inhibitor programs
Cash runway risk: With $80-100M annual burn and current cash position, company likely needs additional financing within 12-18 months; dilution risk to existing shareholders
Equity financing dependency: Market conditions for biotech IPOs and follow-on offerings volatile; adverse sentiment could force financing at unfavorable terms or delay critical trials
Minimal debt capacity: Low revenue and negative cash flow limit ability to raise non-dilutive debt financing; reliance on equity markets creates valuation vulnerability
low - Clinical trial timelines and FDA regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact: (1) ability to raise capital at attractive valuations, (2) pharma partnership activity as larger companies reduce business development spending, (3) patient enrollment if economic stress affects healthcare access. Cancer treatment demand is non-discretionary and recession-resistant.
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (DCF models for pre-revenue biotech are highly rate-sensitive). Higher rates also increase opportunity cost of capital, making speculative biotech less attractive vs. risk-free bonds. Financing costs rise modestly if company taps debt markets, though equity remains primary funding source. Rate environment significantly affects M&A valuations and partnership economics.
Minimal direct credit exposure. Company has low debt (Debt/Equity 0.08) and strong current ratio (5.12x) indicating solid liquidity position. Primary credit risk is access to capital markets for future equity raises - tighter credit conditions can spill over to equity markets, making dilutive financing more expensive or unavailable. Biotech sector financing windows can close during credit stress periods.
growth - High-risk, high-reward clinical-stage biotech attracts speculative growth investors and specialized healthcare funds willing to underwrite binary clinical trial outcomes. Investors seek 3-5x returns on successful drug approval but accept total loss risk on trial failure. Not suitable for value or income investors given negative earnings, no dividends, and uncertain commercialization timeline. Typical holders include biotech-focused hedge funds, venture capital, and retail investors with high risk tolerance.
high - Stock exhibits extreme volatility around clinical data releases (30-50% single-day moves common on trial readouts). Small market cap ($700M) and low float amplify price swings. Beta likely >1.5 relative to broader market. Recent 3-month decline of -23.7% reflects sector rotation and risk-off sentiment in speculative biotech. Six-month and one-year returns (13.0%, 5.8%) show high dispersion and event-driven performance pattern typical of clinical-stage names.
